瑞格列奈
固体脂质纳米粒
泊洛沙姆
肺表面活性物质
差示扫描量热法
色谱法
粒径
微乳液
硬脂酸
化学
纳米颗粒
Zeta电位
材料科学
化学工程
有机化学
纳米技术
生物化学
聚合物
共聚物
医学
胰岛素
物理
二甲双胍
物理化学
工程类
热力学
内分泌学
作者
Balaji Maddiboyina,Vikas Jhawat,Ramya Krishna Nakkala,Prasanna Kumar Desu,Gandhi Sivaraman
标识
DOI:10.1007/s40204-021-00174-3
摘要
Repaglinide, a member of the meglitinide class of drugs, is a new anti-diabetic agent that is utilized as an oral hypoglycemic agent. Using glyceryl monostearate, cetyl palmitate, and tristearin as lipids and poloxamer 188 as a surfactant, repaglinide-loaded solid lipid nanoparticles were created. Solid lipid nanoparticles were prepared utilizing an o/w microemulsion technique, which included the lipids glyceryl monostearate and tristearin, as well as waxes such as cetyl palmitate and the surfactant poloxamer 188. The mean particle size of the solid lipid nanoparticles formed was around 339 nm, with an entrapment efficiency of 82.20%. In-vitro release studies continued to be conducted using the dialysis bag diffusion technique. Within 12 h, the cumulative drug release was 88.4%. The results indicate that repaglinide was released more slowly from solid lipid nanoparticles made from tristearin and glyceryl monostearate in an equal ratio. Tristearin found the controlled release and extreme entrapment from other lipid carriers like glyceryl monostearate and cetyl palmitate. Differential scanning calorimetry demonstrates that repaglinide is entangled in amorphous or molecular state within solid lipid nanoparticles. SEM microscopy revealed that the produced repaglinide solid lipid nanoparticles had a spherical shape. After one month of storage at 2-8 °C, short-term stability testing revealed no significant alteration.
科研通智能强力驱动
Strongly Powered by AbleSci AI